Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00234377
Status:
COMPLETED
Last Update Posted:
2013-01-04
First Post:
2005-10-05
Brief Title:
Seroquel Switching Study Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A 12-week International Multicenter Open Label Non-comparative Study to Evaluate the Feasibility of Switching Any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate SEROQUEL in Patients With Schizophrenia
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to document the clinical benefit of quetiapine Seroquel sustained release SR after switching from another ongoing antipsychotic treatment regardless of the reason for the switch
PLEASE NOTE Seroquel SR and Seroquel XR refer to the same formulation The SR designation was changed to XR after consultation with FDA
PLEASE NOTE Seroquel SR and Seroquel XR refer to the same formulation The SR designation was changed to XR after consultation with FDA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None